
Bliss GVS Pharma Ltd Allots 267,250 Equity Shares Under Employee Stock Options Plan
Bliss GVS Pharma Limited announced the allotment of shares under its Employee Stock Options Plan 2019 (ESOP). The ESOP Allotment Committee approved the issue to eligible employees who exercised their stock options on June 11, 2026.The company allocated a total of 2,67,250 equity shares, each with a face value of Re. 1/-.
Consequent to this allotment, the issued, subscribed, and paid-up share capital of Bliss GVS Pharma Limited increased. Prior to the transaction, the company had 10,57,88,973 equity shares aggregating Rs. 10,57,88,973/-. Following the ESOP allotment, the total share capital stands at 10,60,56,222 equity shares, which aggregate Rs. 10,60,56,222/-.
Key financial details of the newly issued shares are as follows:
| Metric | Detail |
|---|---|
| Shares Issued Under ESOP | 2,67,250 |
| Face Value Per Share | Re. 1/- |
| Exercise Price Per Share | Rs. 43/- |
| Premium Per Share | Rs. 42/- |
The newly allotted equity shares will rank pari passu with the company's existing equity shares. Furthermore, a lock-in period has been imposed on these shares for six months from the date of allotment. The expiry date for this lock in is December 11, 2026.
In addition to this transaction, additional details regarding the share capital and its changes are summarized below:
| Description | Previous Capital | Post Allotment Capital |
|---|---|---|
| Total Equity Shares (Re. 1/- each) | 10,57,88,973 | 10,60,56,222 |
The allotment and subsequent changes ensure that all equity shares of the company are in compliance with established guidelines for employee stock benefit plans.
BLISSGVS Stock Price Movement
Bliss GVS Pharma Limited shares climbed today, closing at ₹436.55 after seeing a gain of 3.14%. The stock managed to trade within an intraday range established between ₹424 and ₹440 amid robust buying interest from over 1.1 million shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.